NCT01629615 2020-10-28
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
SOLTI Breast Cancer Research Group
Phase 2 Completed
SOLTI Breast Cancer Research Group
Novartis
Novartis
Dana-Farber Cancer Institute
Novartis
Duke University
Novartis